METHODS AND MEDICAL DEVICES FOR ANALYZING EPITHELIAL BARRIER FUNCTION

Abstract

The present invention relates to a medical device and a method for assessing and monitoring epithelial barrier function in vivo of a subject using electrical impedance measurements. The method comprises initiating an impedance measurement session including passing an electrical current through the skin of the subject to obtain values of skin impedance of a target tissue region, said data comprising at least one impedance value measured in the target tissue region at different tissue layers. Further, an evaluation procedure is applied for analyzing the epithelial barrier function in the target tissue region based on the measured data set of impedance values for the target tissue region at different tissue layers. The procedure evaluates the obtained data set of impedance values to provide an outcome indicating a status of the epithelial barrier function of the subject.

Claims

1-14. (canceled)

15. A method for assessing and monitoring epithelial barrier function of a subject in vivo using electrical impedance measurements comprising: initiating an impedance measurement session including passing an electrical current through skin of the subject to obtain data of skin impedance of a target tissue region using a plurality of electrodes adapted to be placed in contact with the target tissue region, wherein each electrode is provided with spikes, thereby forming a spiked surface, said data comprising at least one impedance value measured in the target tissue region at different tissue layers; selectively activating electrode pairs to gradually scan tissue of the subject so as to obtain a sequence of impedance signals from selected tissue depths; applying an evaluation procedure for analyzing the epithelial barrier function in the target tissue region based on of the measured data of impedance values for the target tissue region at different tissue layers; and evaluating the measured data of impedance values to provide an outcome indicating a status of the epithelial barrier function of the subject.

16. The method of claim 15, further comprising determining atopic dermatitis (AD) of a patient using the evaluating the measured data, wherein a decrease of impedance of over time indicates AD.

17. The method of claim 15, wherein a decreased electrical impedance (EI) and increased transepidermal water loss (TEWL) measured at a body site of an AD patient compared to a non-lesional skin site of the AD patient indicates a lesion at the body site.

18. The method of claim 15, wherein a differentiation in electrical impedance (EI) between non-lesional skin of an AD patient and healthy skin of a healthy subject is used to predict AD of subjects.

19. The method of claim 15, wherein the step of evaluating comprises analyzing a magnitude of at least one measured impedance value and determining a reduction of the magnitude to indicate an impaired or decreased epithelial barrier function of the subject.

20. The method of claim 15, wherein reference data and/or clinical data is used in the evaluating.

21. The method of claim 20, wherein the reference data and/or clinical data includes tissue data.

22. The method of claim 20, wherein the reference data and/or clinical data is based on earlier measurements of skin impedance of at least one patient.

23. The method of claim 15, wherein, further comprising: applying a trained evaluation procedure for analysis of the measured data of impedance values, wherein said trained evaluation procedure performs: extracting impedance data from impedance spectra from obtained data sets of impedance values reflecting tissue characteristics of epithelial barrier function; and evaluating the extracted impedance data to provide the outcome indicating a status of the epithelial barrier function of the subject.

24. A method for determining patient response in vivo of a drug using electrical impedance measurements comprising: initiating an impedance measurement session including passing an electrical current through skin of a subject to obtain data of skin impedance of a target tissue region using a plurality of electrodes adapted to be placed in contact with the target tissue region, wherein each electrode is provided with spikes, thereby forming a spiked surface, said data comprising at least one impedance value measured in the target tissue region at different tissue layers; selectively activating electrode pairs in to gradually scan tissue of the subject so as to obtain a sequence of impedance signals from selected tissue depths; applying an evaluation procedure for analyzing an epithelial barrier function in the target tissue region based on of the measured data of impedance values for the target tissue region at different tissue layers; evaluating the measured data of impedance values to provide an outcome indicating a status of the epithelial barrier function of the subject; and determining a patient response to the drug based on status of the epithelial barrier function and clinical data including drug prescription.

25. The method of claim 24, wherein the step of evaluating comprises analyzing a magnitude of at least one measured impedance value and determining a reduction of the magnitude to indicate an impaired or decreased epithelial barrier function of the subject.

26. The method of claim 24, wherein reference data and/or clinical data is used in the evaluating.

27. The method of claim 26, wherein the reference data and/or clinical data includes tissue data.

28. The method of claim 27, wherein the reference data and/or clinical data is based on earlier measurements of skin impedance of at least one patient.

29. The method of claim 24, further comprising: applying a trained evaluation procedure for analysis of the measured data of impedance values, wherein said trained evaluation procedure performs: extracting impedance data from impedance spectra from obtained data sets of impedance values reflecting tissue characteristics of epithelial barrier function; and evaluating the impedance data to provide the outcome indicating a status of the epithelial barrier function of the subject.

30. A method for screening epithelial barrier function of subjects in vivo using electrical impedance measurements comprising: performing impedance measurement sessions of subjects including passing an electrical current through skin of each subject to obtain data of skin impedance of a target tissue region using a plurality of electrodes adapted to be placed in contact with the target tissue region, wherein each electrode is provided with spikes, thereby forming a spiked surface, said data comprising at least one impedance value measured in the target tissue region at different tissue layers for each subject; selectively activating electrode pairs to gradually scan tissue of the subject so as to obtain a sequence of impedance signals from selected tissue depths; applying an evaluation procedure for analyzing epithelial barrier function in the target tissue region based on of the measured data of impedance values for the target tissue region at different tissue layers for each subject; and evaluating the measured data of impedance values to provide an outcome indicating a status of the epithelial barrier function of each subject.

31. The method of claim 30, wherein the step of evaluating comprises analyzing a magnitude of at least one measured impedance value and determining a reduction of the magnitude to indicate an impaired or decreased epithelial barrier function of the subject.

32. The method of claim 30, wherein reference data and/or clinical data is used in the evaluating.

33. The method of claim 32, wherein the reference data and/or clinical data includes tissue data.

34. The method of claim 32, wherein the reference data and/or clinical data is based on earlier measurements of skin impedance of at least one patient.

35. The method of claim 30, further comprising: applying a trained evaluation procedure for analysis of the measured data of impedance values, wherein said trained evaluation procedure performs: extracting impedance data from impedance spectra from obtained data sets of impedance values reflecting tissue characteristics of epithelial barrier function; and evaluating extracted impedance data to provide the outcome indicating a status of the epithelial barrier function of the subject.

36. A medical device for assessing and monitoring epithelial barrier function of a subject in vivo using electrical impedance measurements, said medical device comprising: an impedance measuring unit configured to pass an electrical current through skin of the subject to obtain values of skin impedance of a target tissue region, said impedance measuring unit comprising a plurality of electrodes adapted to be placed in contact with the target tissue region, wherein each electrode is provided with spikes, thereby forming a spiked surface, said values comprising at least one impedance value measured in the target tissue region at different tissue layers; a switching circuit adapted to activate adjacent electrodes in a successive manner to gradually scan tissue of the subject at a first tissue depth so as to obtain a sequence of impedance signals from a selected tissue depth; and an evaluation unit configured to apply an evaluation procedure for analyzing the epithelial barrier function in the target tissue region based on the measured data of impedance values for the target tissue region at different tissue layers and to evaluate the measured data of impedance values to provide an outcome indicating a status of the epithelial barrier function of the subject.

37. The medical device of claim 36, wherein said evaluation unit is configured to determine atopic dermatitis (AD) of a patient using a result of the evaluating of the measured data, wherein a decrease of impedance compared to non-lesional skin indicates AD.

38. A medical device for determining patient response in vivo of a drug using electrical impedance measurements comprising: an impedance measuring unit configured to pass an electrical current through skin of a subject to obtain data of skin impedance of a target tissue region, said impedance measuring unit comprising a plurality of electrodes adapted to be placed in contact with tissue, wherein each electrode is provided with spikes, thereby forming a spiked surface, said data comprising at least one impedance value measured in the target tissue region at different tissue layers, said impedance measuring unit being configured to initiate an impedance measurement session including passing the electrical current through the skin of the subject to obtain values of skin impedance of the target tissue region using the plurality of electrodes, selectively activate electrode pairs in to gradually scan tissue of the subject so as to obtain a sequence of impedance signals from selected tissue depths; and an evaluation unit configured to apply an evaluation procedure for analyzing epithelial barrier function in the target tissue region based on of the measured data of impedance values for the target tissue region at different tissue layers; evaluate the impedance values to provide an outcome indicating a status of the epithelial barrier function of the subject; and determine the patient response of the drug based on status of the epithelial barrier function and clinical data including drug prescription.

39. A medical device for assessing and monitoring epithelial barrier function of a subject in vivo using electrical impedance measurements, said medical device comprising: an impedance measuring unit configured to pass an electrical current through skin of the subject to obtain data of skin impedance of a target tissue region, said impedance measuring unit comprising a plurality of electrodes adapted to be placed in contact with the target tissue region, wherein each electrode is provided with spikes, thereby forming a spiked surface, said data comprising at least one impedance value measured in the target tissue region at different tissue layers; a switching circuit adapted to activate adjacent electrodes in a successive manner to gradually scan tissue of the subject at a first tissue depth so as to obtain a sequence of impedance signals from a selected tissue depth; and an evaluation unit configured to apply an evaluation procedure for analyzing the epithelial barrier function in the target tissue region based on the measured data of impedance values for the target tissue region at different tissue layers and to evaluate the impedance values to provide an outcome indicating a status of the epithelial barrier function of the subject; wherein the evaluation unit is configured to use a trained evaluation procedure for analysis of the measured data of impedance values, wherein said trained evaluation procedure performs: extracting impedance data from impedance spectra from obtained data sets of impedance values reflecting tissue characteristics of epithelial barrier function, said extracted impedance data including magnitude information comprising absolute value of magnitude, magnitude gradient, and/or phase information comprising phase angle; and evaluating the extracted impedance data to provide the outcome indicating a status of the epithelial barrier function of the subject.

40. The medical device according to claim 39, wherein said evaluation unit is configured to determine atopic dermatitis (AD) of a patient using an output of the evaluating of the obtained data, wherein a decrease of impedance compared to non-lesional skin indicates AD.

41. The medical device according to claim 39, wherein said evaluation unit is configured to determine atopic dermatitis (AD) of a patient using the evaluating of the obtained data, wherein a decrease of impedance of over time indicates AD.

42. The medical device according to claim 39, wherein said evaluation unit is configured to determine a decreased electrical impedance, EI, and increased transepidermal water loss, TEWL, measured at a body site of an AD patient compared to a non-lesional skin site of the AD patient to indicate a lesion at the body site.

43. The medical device according to claim 39, wherein said evaluation unit is configured to determine a differentiation in electrical impedance, EI, between non-lesional skin of an AD patient and healthy skin of a subject in order to predict AD of subjects.

44. A medical device for determining patient response in vivo of a drug using electrical impedance measurements comprising: an impedance measuring unit configured to pass an electrical current through skin of a subject to obtain data of skin impedance of a target tissue region, said impedance measuring unit comprising a plurality of electrodes adapted to be placed in contact with the target tissue region, wherein each electrode is provided with spikes, thereby forming a spiked surface, said data comprising at least one impedance value measured in the target tissue region at different tissue layers; a switching circuit adapted to activate adjacent electrodes in a successive manner to gradually scan tissue of the subject at a first tissue depth so as to obtain a sequence of impedance signals from a selected tissue depth; an evaluation unit configured to apply an evaluation procedure for analyzing epithelial barrier function in the target tissue region based on the measured data of impedance values for the target tissue region at different tissue layers and to evaluate the impedance values to provide an outcome indicating a status of the epithelial barrier function of the subject; and wherein the evaluation unit is configured to use a trained evaluation procedure for analysis of the measured data of impedance values, wherein said trained evaluation procedure performs: extracting impedance data from impedance spectra from obtained data sets of impedance values reflecting tissue characteristics of epithelial barrier function, said extracted impedance data including magnitude information comprising absolute value of magnitude, magnitude gradient, and/or phase information comprising phase angle; and evaluating the extracted impedance data to provide the outcome indicating a status of the epithelial barrier function of the subject; wherein said evaluation unit is configured to determine the patient response of the drug based on status of epithelial barrier function and clinical data including drug prescription.

45. The medical device according to claim 44, wherein reference data and/or clinical data is used in the evaluating.

46. A medical device for determining patient response in vivo of a drug using electrical impedance measurements comprising: an impedance measuring unit configured to pass an electrical current through the skin of a subject to obtain data of skin impedance of a target tissue region, said impedance measuring unit comprising a plurality of electrodes adapted to be placed in contact with tissue, wherein each electrode is provided with spikes, thereby forming a spiked surface, said data comprising at least one impedance value measured in the target tissue region at different tissue layers, said impedance measuring unit being configured to initiate an impedance measurement session including passing the electrical current through the skin of the subject to obtain values of skin impedance of a target tissue region using the plurality of electrodes, selectively activate electrode pairs in to gradually scan tissue of the subject so as to obtain a sequence of impedance signals from selected tissue depths; and an evaluation unit configured to apply an evaluation procedure for analyzing epithelial barrier function in the target tissue region based on of the measured data of impedance values for the target tissue region at different tissue layers; evaluate the impedance values to provide an outcome indicating a status of the epithelial barrier function of the subject; and determine the patient response of the drug based on status of epithelial barrier function and clinical data including drug prescription.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Exemplifying embodiments of the invention will be described below with reference to the accompanying drawings, in which:

[0034] FIG. 1 is a schematic block diagram of one embodiment of a medical device according to the present invention;

[0035] FIG. 2a-c: Epicutaneous administration of increasing concentrations of papain damages the epithelial barrier, causing a dose-dependent decrease of EI and increase of TEWL of skin;

[0036] FIG. 3a-c: Papain downregulates the expression of molecules involved in the epithelial barrier function;

[0037] FIG. 4a-c: Trypsin shows a similar effect on skin epithelial barrier, causing a decrease of EI and an increase of TEWL;

[0038] FIG. 5a-b: Tape stripping leads to a reduction of EI and an increase of TEWL of the skin.

[0039] FIG. 6: Cholera toxin decreases EI of skin ex vivo.

[0040] FIG. 7: Electrical impedance measured at the superficial layer shows a stronger decrease when compared to the deeper layer after papain treatment and tape stripping.

[0041] FIG. 8: Nyquist plot showing the effect of papain on the EI represented as a vector on a Nyquist Plot where the two components of the EI, the real part and the imaginary part, are plotted on the X and Y axes.

[0042] FIG. 9 AD patients show significantly decreased EI values compared to healthy subjects and their lesions are characterized by a decrease of EI and an increase of TEWL, if compared to non-lesional skin.

[0043] FIG. 10 Lesional skin shows an increase of EI and a decrease of TEWL during the 21 day treatment.

DESCRIPTION OF EXEMPLIFYING EMBODIMENTS

[0044] The following is a description of exemplifying embodiments in accordance with the present invention. This description is not to be taken in limiting sense, but is made merely for the purposes of describing the general principles of the invention. Even though particular types of probes including micro-invasive as well as non-invasive will be described, the invention is also applicable to other types of such as invasive probes.

[0045] Thus, preferred embodiments of the present invention will now be described for the purpose of exemplification with reference to the accompanying drawings, wherein like numerals indicate the same elements throughout the views. It should be understood that the present invention encompasses other exemplary embodiments that comprise combinations of features as described in the following. Additionally, other exemplary embodiments of the present invention are defined in the appended claims.

[0046] Referring first to FIG. 1, a general description of a medical device according to the present invention will be discussed. The device 10 comprises an impedance measuring circuit or unit 2 and a analyzing or evaluation unit 4 for analyzing the epithelial barrier function in the target tissue region on the basis of the measured data set of impedance values for the target tissue region at different tissue layers and evaluating the obtained data set of impedance values to provide an outcome indicating a status of the epithelial barrier function of the subject. The impedance measuring unit 2 is adapted to obtain impedance data of a target tissue region of the tissue of the subject. It is to be understood that the impedance data of the target tissue region comprises at least one impedance value obtained at different tissue depths (or layers), for example, at four different depths, and over a spectrum of frequencies, for example, at 35 different frequencies from 1 kHz to 2.5 MHz.

[0047] The tissue impedance measurement for obtaining the impedance data of the target tissue region may be performed by means of a probe 8 integrated in the medical device 10 or a probe being external to the medical device 10 and connected to the medical device 10. Irrespective of being external or integrated, the probe may comprise a plurality of electrodes 14 adapted to be placed in contact with the tissue to be analyzed, typically skin of the subject. The tissue impedance may be measured by applying an AC voltage over a pair of electrodes and measure the resulting current passing the same pair of electrodes. In embodiments, 2-point measurements are used by applying voltage and measure current over one pair of electrodes. The remaining electrodes may be grounded or free floating. In embodiments of the present invention, the probe 8 comprises, for example, seven or five electrodes, e.g. shaped as rectangular electrode bars. The electrodes are adapted to be placed in direct contact with the skin.

[0048] In an embodiment, adjacent electrodes are separated with a distance of about 0.3 mm and having a length of about 5 mm, has shown to be a practical and useful configuration for detections of diseased conditions such as malignant melanoma, both with regard to spatial resolution in a lateral dimension and in a depth dimension. A skin area of about 5×5 mm or about 25 mm.sup.2 is thus covered by the probe and at high frequencies, above about 100 kHz, the deepest tissue layer being reached is about 2.5 mm which has been proven to be a clinical relevant depth. In order to cover a larger skin area, the probe can be moved to a neighboring skin site. However, as the skilled person realizes, the probe may include more or less than seven electrodes, for example 3, 4, 5 or 9 electrodes. Further, other electrode dimensions, geometries and other spacing between adjacent electrodes are conceivable, for example, electrodes having a width of about 4 mm and a length of about 8 mm.

[0049] By selecting adjacent pairs of electrodes, the topmost layer of the skin can be scanned in steps, and by selecting pairs that are spaced further apart, i.e. electrode pairs with one or more intermediate electrodes, the resulting current path allows for measurement at deeper skin layers. The possibility to measure inter alia the topmost skin layer in small (determined inter alia by the spacing between adjacent electrodes and the frequency of the applied current) consecutive partitions is important since it allows for detection of small anomalies in the skin and tissue. Each electrode of the probe may be set in four different states including inject (the electrode is set to inject measurement current into the tissue), measure (the resulting current from the tissue is measured via the electrode), ground (the electrode is grounded to prevent leakage of superficial current when measurements are performed using other electrodes) and floating (the electrode is disconnected).

[0050] The evaluation unit 4 may include storage units (not shown) for storing, for example, obtained impedance data performed on the patient. The diagnosing unit 4 may also include a processing circuit 5, in this embodiment included in the diagnosing unit 4, adapted to process obtained impedance data to reduce the number of variables by removing insignificant variables by performing linear or non-linear projections of the impedance data to lower subspaces. In preferred embodiments of the present invention, principal component analysis (PCA) is used. An alternative approach is to use parallel factor analysis (PARAFAC). Further, classification rules determined by means of, for example, linear discriminant analysis (LDA) or soft independent modelling of class analogy (SIMCA) may be used to improve the evaluation.

[0051] Moreover, the evaluation unit 4 may communicate with display means for displaying, for example, an epithelial skin barrier status. The evaluation unit 4 applies an evaluation procedure for analyzing the epithelial barrier function in the target tissue region on the basis of the measured data set of impedance values for the target tissue region at different tissue layers and evaluates the obtained data set of impedance values to provide an outcome indicating a status of the epithelial barrier function of the subject. A magnitude of the measure impedance may be determined and reduction or decrease of the magnitude indicates an impaired or decreased epithelial barrier function of the subject. Reference data and/or clinical data may be used in the evaluation. In embodiments of the present invention, the evaluation unit 4 may use a trained evaluation procedure for analysis of the measured data set of impedance values, wherein the trained evaluation procedure extracts impedance data from the impedance spectra from obtained data sets of impedance values reflecting tissue characteristics of epithelial barrier function and evaluates the obtained data set of impedance to provide the outcome indicating a status of the epithelial barrier function of the subject.

[0052] According to embodiments of the present invention, each electrode is provided with spikes, thereby forming a spiked surface. As has been discussed above, the probe, in preferred embodiments, may include five rectangular areas or bars. In this configuration, each bar contains an array of, for example, 45 (15×3) or, 57 (19×3) micro-spikes. Each bar is about 0.75 mm wide and 5 mm long. The distance between adjacent bars is about 0.2-0.5 mm. The active part of the probe is thus about 5×5 mm. Each micro-spike has a length of approximately 100 micrometer, as measured from its base, and a thickness of at least 20 micrometer. The electrode bars and micro-spikes can be made of plastic material in a moulding process. The material could be made intrinsically conductive or covered with a conductive layer such as gold. In an alternative embodiment, the electrode bars and micro-spikes are made of, for example, plastic or silicon and covered with metal, for example, gold having a thickness of at least 1 micrometer. However, other materials comprising a conductive surface with similar dimensions would work, but it should be selected to be biocompatible. In, for example, the patent applications EP 1959828, EP 1600104, and EP 1437091 by the same applicant, different probe concepts having such micro-spikes are described.

[0053] In another embodiment, the electrode bars are non-invasive and substantially flat. In, for example, U.S. Pat. No. 5,353,802 by the same applicant, a probe concept including non-invasive electrodes has been described.

[0054] In other embodiments of the present invention, the probe is spherically shaped, i.e. the surface including the electrodes that is pressed against the skin or tissue during a measurement has a spherical shape. This also means that the electrodes may be at least partly spherically shaped.

[0055] For example, each spike may have a length of 0.01 to 1 mm. The spikes may be arranged on electrodes, in turn arranged on the probe, where each electrode may comprise from at least two spikes to about 100-200 spikes in certain applications, and any number in between. In the U.S. Pat. No. 9,636,035 by the same applicant, examples of preferred embodiments of spike designs are described. By such configurations of spikes an increased versatility and increased adaptability in terms of capacity requirements can be achieved, in addition to possibly alleviating the problem of non-linear effects of the stratum corneum.

[0056] A control circuit 9 may be configured to control, for example, switching cycles/sequences of the electrodes 14 in accordance with a predetermined activation procedure or scheme. This predetermined activation scheme may include an activation of adjacent electrode in a successive manner to gradually scan tissue of the subject at a first tissue depth, which scanned tissue depends to a large extent on spacing between activated electrode pairs so as to obtain a matrix of impedance signals from different tissue depths.

[0057] The evaluation unit 4 is configured to pre-process the impedance data, for example, reduction of noise content and/or reduction of the dimensionality. The noise reduction may include reduction of noise in the impedance magnitude and/or phase angle spectra. The noise reduction may for example be made with the use of a Savitsky-Golay smoothing filter. Data on the subject's physical conditions may also be utilized by the diagnosing unit 4 and the data on the physical conditions may be parameterized and further used in the diagnosing process. Further, the pre-processing may comprise detection and correction of spikes or other artefacts, enabling removal of spikes or artefacts in the impedance spectrum, i.e. magnitude and/or phase angle spectra. Spikes may for example be detected with a median filter with an adequate window size. Data points of the filtered data that differ too much from raw data may be considered to be a spike or other artefact and may be corrected by e.g. linear interpolation.

[0058] The evaluation unit 4 may further comprise a pre-filter enabling rejection of measurement that do not fulfill one or a few specific criteria, such as cut-offs. The pre-filter may be applied on impedance data that has been corrected/adjusted e.g. by pre-processing as discussed above. For example, the magnitude values and/or phase angle values may all be required to fall within a specified magnitude range of a specified phase range, respectively, in order for a measurement not to be rejected. If the measurement is on a human/animal skin, the criteria, such as the ranges, may be set such as non-physiological measurements are rejected. Also, a specific criteria may be set for a certain value relating to a specific frequency.

[0059] The evaluation unit 4 may further include a classifier to assess whether quality of measured impedance data is good. This procedure may be combined with pre-processing and/or pre-filtering to further improve quality of the data. Examples of such classification include assessment of the variation, e.g. the variance or standard deviation, of magnitude and/or phase angle in different permutations at one or a plurality of frequencies. Further examples encompass the absolute values of magnitude and/or phase angles that may be studied, for example the median value or average value, skewness of magnitude, derivative of magnitude or phase angle, or phase angle.

[0060] The medical device 10 may further include a communication unit 12 capable of transmitting/receiving data to/from external units 15, such as a laptop computer, a handheld computer/device, a computer embedded into the device, a database, a cloud-based arrangement, etc., directly with the unit or network itself or via a wireless network 16. In this way, the device 10 may be supplied with, for example, clinical data for use in the evaluation. Moreover, data obtained with the medical device 10 such as impedance data from measurements can also be downloaded to external devices 15 via the communication unit 12.

[0061] Furthermore, the medical device 10 includes a pressure applying unit 18 configured to apply a predetermined pressure on the tissue or skin when activated and the probe 8 is pressed against the tissue or skin during the measurement. Preferably, the pressure is constant during the measurement session. For example, a pressure in a range of 1-12 N may be applied, or in preferred embodiments a pressure in a range of 3-10 N, or in further preferred embodiments in a range of 5-7 N or as in a certain embodiments in a range of 5.5-6.5 N. In embodiments of the present invention, the applied predetermined pressure may be combined with or replaced by a sucking action, which thus attaches the probe to the tissue or skin during the measurement.

[0062] It is to be understood that in the context of the present invention and in relation to electrical components electrically connected to each other, the term connected is not limited to mean directly connected, but also encompasses functional connections having intermediate components. For example, on one hand, if an output of a first component is connected to an input of a second component, this comprises a direct connection. On the other hand, if an electrical conductor directly supplies a signal from the output of the first component substantially unchanged to the input of the second component, alternatively via one or more additional components, the first and second components are also connected. However, the connection is functional in the sense that a gradual or sudden change in the signal from the output of the first component results in a corresponding or modified change in the signal that is input to the second component.

[0063] Although exemplary embodiments of the present invention has been shown and described, it will be apparent to those having ordinary skill in the art that a number of changes, modifications, or alterations to the inventions as described herein may be made. Thus, it is to be understood that the above description of the invention and the accompanying drawings is to be regarded as a non-limiting example thereof and that the scope of protection is defined by the appended patent claims.

Test Results

[0064] Hence, the inventors have found that EI spectroscopy can be used for the tin vivo detection of the epithelial barrier function. As shown in FIG. 2 a dose-dependent reduction of EI was detected as early as 1 hour after the treatment, reflecting the decreased epithelial barrier function.

[0065] EI spectroscopy determinations show a clear negative correlation with another biomarker of epithelial barrier damage in the skin, which is transepidermal water loss (TEWL). The increase in TEWL demonstrates barrier damage which is in parallel to decrease in EI spectroscopy that also demonstrates barrier damage. In addition, to show clearly the effect of papain on the EI, we represented it as a vector on a Nyquist Plot, by plotting the two components of the EI, the real part and the imaginary part, on the X and Y axes, see FIG. 8. We clearly observed that at 5 hours from the papain application, the curves obtained were significantly different from the ones obtained in the control mice, in which only PBS was epicutaneously applied.

[0066] Barrier disruption induced by papain was confirmed by histological analysis, which showed an impaired stratum corneum and higher cellular infiltration after papain application, FIG. 3a. In addition, we checked the expression of molecules important for the skin barrier function, such as Filaggrin or the TJ molecules occludin and claudin-1 by immunofluorescence staining. Downregulation of the expression of all three barrier molecules was observed in a dose-dependent manner, FIGS. 4a and 4b.

[0067] EI spectroscopy detects epithelial barrier as it decreases together with the damage of epithelial barrier molecules as demonstrated by decreased mRNA expressions of filaggrin, loricrin and involucrin, demonstrating overall impairment of the stratum corneum barrier function. These results confirmed the impairment of the skin barrier function by papain treatment and its demonstration by EI spectroscopy.

[0068] The effect of another protease, the serine protease trypsin, which was applied epicutaneously to mice skin by following the same protocol used for the papain application. As shown in FIG. 3, a significant decrease of EI and a simultaneous significant increase of TEWL after trypsin treatment, consistent with the data in papain exposure. Similarly, EI and TEWL values showed significant inverse correlation.

[0069] To further investigate the accuracy of epithelial barrier detection, we tested the EI and TEWL methods on nude mice skin after damaging the epithelial barrier by tape stripping, a simple and efficient method through which the cell layers of the stratum corneum are successively removed by using adhesive films. EI and TEWL measurements have been performed before tape stripping and immediately after 5, 10, 15 and 20 tape strips. We detected a significant reduction of EI after tape stripping, reflecting the decreased epithelial barrier function. In parallel measurements, we observed an increase of TEWL, confirming that the skin surface barrier function was reduced, FIG. 5a. The same protocol was followed in human healthy volunteers, in whom results obtained in mice were confirmed with a reduction of EI and an increase of TEWL observed after tape stripping FIG. 5b.

[0070] Epithelial barrier damage induced by cholera toxin is detected by EI spectroscopy. Back skin from C57BL/6 nude mice was isolated and incubated at 37° C. for 1 h in presence of 2 μg/ml cholera toxin. We observed that after one hour cholera toxin treatment, the EI was significantly reduced, in comparison to the control condition with PBS treatment, FIG. 6. Once again, our observations indicate the validity of EI spectroscopy as a method to detect epithelial barrier function.

[0071] The data demonstrates that EI spectroscopy can be a direct method to assess the skin epithelial barrier function tin vivo. Based on our results, EI spectroscopy represents a good candidate approach for the study of and characterization of skin inflammatory disorders, such as AD. AD affects up to 20% of children and up to 4.9% of adults (Ref 21, 22). The hallmark features are itch and eczematous skin lesions that manifest often in early infancy with a course of remissions and exacerbations. An impaired epidermal barrier, characterized both by defective filaggrin protein expression and TJ defects, has been described (Ref 23). EI spectroscopy facilitate the early diagnosis of AD in infants, allowing the identification of the risk of the disorder and thus the possibility to apply preventive measures. Furthermore, EI spectroscopy can be used for follow-up of cutaneous lesions to obtain information on the effect of a topical or systemic treatment and gather additional information for monitoring the stage and severity of a lesion. Moreover, it may also be a useful non-invasive, cost-effective tool for the overall clinical assessment for the follow-up of a patient, without performing sophisticated assays for barrier evaluation, such as the analyses of filaggrin mutations from DNA.

[0072] FIG. 9 illustrates test results where AD patients show significantly decreased EI values compared to healthy subjects and their lesions are characterized by a decrease of EI and an increase of TEWL, if compared to non-lesional skin. EI (a) and TEWL (b) were measured in healthy controls and AD patients in the same body site. In patients measurements were performed both on a lesion and on a non-lesional area close to that lesion. EI is expressed in kOhm, at the frequency of 1000 Hz. TEWL is expressed in g/m2 h. *: p<0.05, **: p<0.01, ****: p<0.0001.

[0073] FIG. 10 illustrates test results where lesional skin shows an increase of EI and a decrease of TEWL during the 21 days treatment. T0 relates to the measurement at the first visit at the clinic, T01 is a the visit in the middle of the treatment and T02 the final visit. EI (a) and TEWL (b) were measured in AD patients in the same body site over a time of 21 days, which corresponds to the duration of the treatment at the clinic. EI is expressed in kOhm, at the frequency of 1000 Hz. TEWL is expressed in g/m2 h. *: p<0.05, **: p<0.01.

Description of Test Result Figures

[0074] FIG. 2: Epicutaneous administration of increasing concentrations of papain damages the epithelial barrier, causing a dose-dependent decrease of EI and increase of TEWL of skin. WT C57BL/6 mice were depilated on their back by using a depilatory cream. Three days after depilation 100 μl of a solution containing different doses of the protease papain (0.1 μg/μl, 1 μg/μl and 10 μg/μl), or PBS as control (unstimulated), by means of a skin patch. EI (a) and TEWL (b) measurements were performed before treatment and 1, 3, 5, 24, 48, 72 hours after the treatment. (c) Spearmen correlation between EI and TEWL is shown for each time point. Electrical impedance is expressed in kOhm, at the frequency of 1000 Hz. TEWL is expressed in g/m2 h. Data are shown as mean±SD (n=8). *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001

[0075] FIG. 3: Papain downregulates the expression of molecules involved in the epithelial barrier function. (a) Hematoxylin and eosin staining, immunofluorescence staining of filaggrin, occludin and claudin-1 of mice skin after applying epi-cutaneously PBS as control or 100 μl of a solution containing increasing doses of the papain (0.1 μg/μl, 1 μg/μl and 10 μl/μl). (b) mRNA expression of filaggrin, involucrin, loricrin, keratin-10, claudin-1 and occludin 5 hours after the epicutaneous treatment with different doses of papain.

[0076] FIG. 4: Trypsin shows a similar effect on skin epithelial barrier, causing a decrease of EI and an increase of TEWL. WT C57BL/6 mice were depilated on their back. Three days after depilation, 100 μl of a solution containing trypsin (0.5%), or the cysteine protease papain (10 μg/μl), or PBS as control, by means of a skin patch. EI (a) and TEWL (b) measurements were performed before treatment and 1, 3, 5 and 24 h after the treatment. (c) Correlation between EI and TEWL is shown for each time point. Electrical impedance is expressed in kOhm, at the frequency of 1000 Hz. TEWL is expressed in g/m.sup.2 h. Data are shown as mean±SD (n=8). *: p<0.05, **: p<0.01.

[0077] FIG. 5: Tape stripping leads to a reduction of EI and an increase of TEWL of the skin. (a) C57BL/6 nude mice skin was damaged by tape stripping, an efficient approach through which the cell layers of the stratum corneum are successively removed by using adhesive films. EI and TEWL measurements were performed before tape stripping and after 5, 10, 15 and 20 tape strips. (b) Same protocol was followed in human subjects. Electrical impedance is expressed in kOhm, at the frequency of 1000 Hz. TEWL is expressed in g/m.sup.2 h. Data are shown as mean±SD, n=12 (a), 5 (b). *: p<0.05, **: p<0.01. ***: p<0.001.

[0078] FIG. 6: Cholera toxin decreases EI of skin ex vivo. Back skin from C57BL/6 nude mice was isolated and incubated at 37° C. for 1 h in presence of 2 μg/ml cholera toxin (B), a microbial product which can specifically destroy the epithelial TJs. Electrical impedance is expressed in kOhm, at the frequency of 1000 Hz. Data are shown as mean±SD, n=5 in A and n=7 in B. *: p<0.05.

[0079] FIG. 7: Electrical impedance measured at the superficial layer shows a stronger decrease when compared to the deeper layer after papain treatment and tape stripping. Electrical impedance can be measured at several different depths. Electrical impedance, expressed in kOhm at the frequency of 1000 Hz, is shown at depth a, the most superficial depth, and at depth b, the deepest depth, before the treatment with PBS (control) and papain (10 μg/μl) and after 1, 3 and 5 hours from the treatment (a) and before tape stripping and after 5 and 10 tape strips (b). *p<0.05, **: p<0.01.

[0080] FIG. 8: Nyquist plot. The electrical impedance is a complex number, composed of a real and an imaginary part. A Nyquist Plot is obtained by plotting the real part on the X-axis and the imaginary part on the Y-axis of. Each point of the curve is the impedance at one frequency. Low frequency data are on the right side of the plot and higher frequencies are on the left.

[0081] FIG. 9 AD patients show significantly decreased EI values compared to healthy subjects and their lesions are characterized by a decrease of EI and an increase of TEWL, if compared to non-lesional skin. EI (a) and TEWL (b) were measured in healthy controls and AD patients in the same body site. In patients measurements were performed both on a lesion and on a non-lesional area close to that lesion. EI is expressed in kOhm, at the frequency of 1000 Hz. TEWL is expressed in g/m2 h. *: p<0.05, **: p<0.01, ****: p<0.0001.

[0082] FIG. 10 Lesional skin shows an increase of EI and a decrease of TEWL during the 21 days treatment. EI (a) and TEWL (b) were measured in AD patients in the same body site over a time of 21 days, which corresponds to the duration of the treatment at the clinic. EI is expressed in kOhm, at the frequency of 1000 Hz. TEWL is expressed in g/m2 h. *: p<0.05, **: p<0.01.

REFERENCES

[0083] 1. Presland R B, Jurevic R J. Making sense of the epithelial barrier: what molecular biology and genetics tell us about the functions of oral mucosal and epidermal tissues. J Dent Educ. 2002; 66(4):564-74. [0084] 2. Tamari M, Tanaka S, Hirota T. Genome-wide association studies of allergic diseases. Allergol Int. 2013; 62(421-8. [0085] 3. Tamari M, Hirota T. Genome-wide association studies of atopic dermatitis. J Dermatol. 2014; 41(3):213-20. [0086] 4. Kubo T, Wawrzyniak P, Morita H, Sugita K, Wanke K, Kast J I, et al. CpG-DNA enhances the tight junction integrity of the bronchial epithelial cell barrier. J Allergy Clin Immunol. 2015; 136(5):1413-6.e1-8. [0087] 5. Kast J I, Wanke K, Soyka M B, Wawrzyniak P, Akdis D, Kingo K, et al. The broad spectrum of interepithelial junctions in skin and lung. J Allergy Clin Immunol. 2012; 130(2):544-7.e4. [0088] 6. Wawrzyniak P, Wawrzyniak M, Wanke K, Sokolowska M, Bendelja K, Rückert B, et al. Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients. J Allergy Clin Immunol. 2016. [0089] 7. Soyka M B, Wawrzyniak P, Eiwegger T, Holzmann D, Treis A, Wanke K, et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4. J Allergy Clin Immunol. 2012; 130(5):1087-96.e10. [0090] 8. Simon D, Page B, Vogel M, Bussmann C, Blanchard C, Straumann A, et al. Evidence of an abnormal epithelial barrier in active, untreated and corticosteroid-treated eosinophilic esophagitis. Allergy. 2018; 73(1):239-47. [0091] 9. Mitamura Y, Nunomura S, Nanri Y, Ogawa M, Yoshihara T, Masuoka M, et al. The IL-13/periostin/IL-24 pathway causes epidermal barrier dysfunction in allergic skin inflammation. Allergy. 2018. [0092] 10. De Benedetto A, Rafaels N M, McGirt L Y, Ivanov A I, Georas S N, Cheadle C, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011; 127(3):773-86.e1-7. [0093] 11. Georas S N, Rezaee F. Epithelial barrier function: at the front line of asthma immunology and allergic airway inflammation. J Allergy Clin Immunol. 2014; 134(3):509-20. [0094] 12. Sandilands A, Sutherland C, Irvine A D, McLean W H. Filaggrin in the frontline: role in skin barrier function and disease. J Cell Sci. 2009; 122(Pt 9):1285-94. [0095] 13. Furuse M. Molecular Basis of the Core Structure of Tight Junctions. Cold Spring Harbor Perspectives in Biology. 2010; 2(1). [0096] 14. Ganesan S, Comstock A T, Sajjan U S. Barrier function of airway tract epithelium. Tissue Barriers. 2013; 1(4):e24997. [0097] 15. Zhang N, Van Crombruggen K, Gevaert E, Bachert C. Barrier function of the nasal mucosa in health and type-2 biased airway diseases. Allergy. 2016; 71(3):295-307. [0098] 16. Schneeberger E E, Lynch R D. The tight junction: a multifunctional complex. Am J Physiol Cell Physiol. 2004; 286(6):C1213-28. [0099] 17. Shin K, Fogg V C, Margolis B. Tight junctions and cell polarity. Annual review of cell and developmental biology. 2006; 22:207-35. [0100] 18. Balda M S, Matter K. Tight junctions and the regulation of gene expression. Biochim Biophys Acta. 2009; 1788(4):761-7. [0101] 19. Assemat E, Bazellieres E, Pallesi-Pocachard E, Le Bivic A, Massey-Harroche D. Polarity complex proteins. Biochim Biophys Acta. 2008; 1778(3):614-30. [0102] 20. Matter K, Balda M S. SnapShot: Epithelial tight junctions. Cell. 2014; 157(4):992-e1. [0103] 21. Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson E L, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018; 73(6):1284-93. [0104] 22. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015; 66 Suppl 1:8-16. [0105] 23. Zaniboni M C, Samorano L P, Orfali R L, Aoki V. Skin barrier in atopic dermatitis: beyond filaggrin. An Bras Dermatol. 2016; 91(4):472-8. [0106] 24. Soyka M B, Wawrzyniak P, Eiwegger T, Holzmann D, Treis A, Wanke K, et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4. J Allergy Clin Immunol. 2012; 130(5):1087-96.e10. [0107] 25. Xian M, Wawrzyniak P, Ruckert B, Duan S, Meng Y, Sokolowska M, et al. Anionic surfactants and commercial detergents decrease tight junction barrier integrity in human keratinocytes. J Allergy Clin Immunol. 2016; 138(3):890-3.e9. [0108] 26. Antonov D, Schliemann S, Elsner P. Methods for the Assessment of Barrier Function. Curr Probl Dermatol. 2016; 49:61-70. [0109] 27. Takai T, Ikeda S. Barrier dysfunction caused by environmental proteases in the pathogenesis of allergic diseases. Allergol Int. 2011; 60(1):25-35.